CorMedix Inc. (CRMD) Set to Announce Earnings on Wednesday
CorMedix Inc. (NYSEMKT:CRMD) is set to release its earnings data after the market closes on Wednesday, August 9th. Analysts expect CorMedix to post earnings of ($0.16) per share for the quarter.
CorMedix Inc. (NYSEMKT:CRMD) traded up 2.029% during trading on Monday, reaching $0.367. The company’s stock had a trading volume of 169,972 shares. CorMedix Inc. has a 52 week low of $0.34 and a 52 week high of $3.26. The company’s market cap is $14.91 million. The company’s 50 day moving average price is $0.42 and its 200 day moving average price is $1.12.
WARNING: “CorMedix Inc. (CRMD) Set to Announce Earnings on Wednesday” was published by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/08/07/cormedix-inc-crmd-set-to-announce-earnings-on-wednesday.html.
In other news, CEO Khoso Baluch bought 75,000 shares of the company’s stock in a transaction dated Wednesday, May 17th. The shares were bought at an average cost of $0.48 per share, with a total value of $36,000.00. Following the acquisition, the chief executive officer now owns 85,000 shares in the company, valued at $40,800. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last ninety days, insiders bought 203,781 shares of company stock worth $98,362.
CRMD has been the topic of a number of research analyst reports. Rodman & Renshaw dropped their target price on shares of CorMedix from $6.00 to $5.00 and set a “buy” rating on the stock in a report on Friday, May 5th. FBR & Co reaffirmed a “buy” rating on shares of CorMedix in a report on Monday, April 24th. Finally, Zacks Investment Research raised shares of CorMedix from a “hold” rating to a “buy” rating and set a $1.25 target price on the stock in a report on Tuesday, April 25th.
CorMedix Company Profile
CorMedix Inc is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications.
Receive News & Ratings for CorMedix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.